Labiotech.eu
- Oncology biotech news: Key moves to watch in November 2026Labiotech.eu ·
Delve into Labiotech's November oncology roundup and find out about the news that caught our attention this last month.
- Chinese biotech competition and the payer squeeze are reshaping European biotechLabiotech.eu ·
At BIO-Europe last week one preclinical company explained how it was building its drug development program with a focus on fitting prescribing and reimbursement models.
- CNS drug discovery: How AI-powered EEG profiling can sharpen go/no-go decisionsLabiotech.eu ·
Learn how quantitative EEG and AI give CNS drug discovery teams the evidence to progress or drop candidates before costly later-stage studies.
- Where is Regeneron headed after record third quarter?Labiotech.eu ·
Coming off one of its strongest quarters in years, Regeneron's pipeline has seen approvals, trial fails, and promising readouts.
- TL1A antibodies: a new inflammatory disease marketLabiotech.eu ·
As late-stage trials accumulate and candidates get closer to market, find out about TL1A, a new class in inflammatory diseases.
- Key takeaways from BIO-Europe 2026: European biotech has the science – but does it have the backing?Labiotech.eu ·
BIO-Europe 2026 highlighted the ambition of Europe’s biotech sector and the obstacles standing between promising science and new medicines.
- Inside Arbor’s CNS pipeline and next-generation gene editingLabiotech.eu ·
Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most.
- Preclinical Pulse: The research catching our eye in November 2026Labiotech.eu ·
Preclinical Pulse in November 2026 features research across therapeutic technologies, including small molecule and gene therapy approaches.
- Biotech in Switzerland: 10 companies to watch in 2027Labiotech.eu ·
Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 10 promising Swiss biotech companies.
- Zooming out from ovaries: how has renaming PMOS changed lives?Labiotech.eu ·
The name change from PCOS to PMOS hopes to reverse misdiagnoses rates and spread awareness about a complex endocrine disorder.
- How to turn a BIO-Europe meeting into a lasting partnershipLabiotech.eu ·
Joining us is Shashi Koduru, Senior Director of Business Development at Vector BioMed. We discuss how he finds the right partners, and makes short meetings productive.
- From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026Labiotech.eu ·
We look at some of the key biotech developments, companies, and clinical data to watch at AHA Scientific Sessions 2026.
- The biggest biotech funding rounds in October 2026Labiotech.eu ·
The companies Summit Therapeutics, Dren Bio, and Lycia Therapeutics bagged the biggest biotech funding rounds overall in October 2026.
- Top biotech deals in October 2026Labiotech.eu ·
The most expensive biotech M&A in October 2026 was worth $2 billion. Licensing deals spanned across therapeutic technologies.
- Why global expansion is changing the shape of the ATMP supply chainLabiotech.eu ·
Explore how integrated infrastructure can help advanced therapy supply chains reduce fragmentation, maintain continuity, and support global growth.
- Teva’s pipeline in 2027: Can it sustain its transformation?Labiotech.eu ·
While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative pipeline.
- ESMO 2026: readouts and highlights at the oncology summitLabiotech.eu ·
ESMO 2026 was the hotspot for cancer research readouts, with encouraging trials across indications and therapeutic candidates.
- Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)Labiotech.eu ·
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes.
- New idiopathic pulmonary fibrosis drugs on the wayLabiotech.eu ·
There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner.
- TROP2 ADCs: The race to capture the next oncology opportunityLabiotech.eu ·
Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs.
- 13 of the best biotech incubators hatching startups in EuropeLabiotech.eu ·
Discover our top picks of biotech incubators in Europe giving life science startups the boost they need to get off the ground.
- The stranded asset problem in microbial custom manufacturingLabiotech.eu ·
Lonza brings over 40 years of experience in microbial manufacturing, spanning pilot-scale development through commercial production.
- Novavax’s new strategy: Betting its future on partnershipsLabiotech.eu ·
Delve into Novavax's pipeline and strategy as the company shifts to a partnership-driven model post-COVID-19.
- Beyond dilation: six biotechs advancing pulmonary hypertension therapiesLabiotech.eu ·
Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.
- GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)Labiotech.eu ·
In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants.
- Oncology biotech news: key moves to watch in October 2026Labiotech.eu ·
Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.
- Shifting the standard: myopia companies to look out forLabiotech.eu ·
Medicines are under review in the clinic to treat myopia. Here are five myopia companies in sight of approval for their therapies.
- Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035Labiotech.eu ·
Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by 2035.
- Great gene editing. Now prove it without overcomplicating the analysisLabiotech.eu ·
Gene editing is moving from lab bench to approved therapies. But how should sponsors measure editing efficiency without unnecessary complexity?
- B7-H3 ADCs: A new contender in small cell lung cancer and beyondLabiotech.eu ·
Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer as Hansoh Pharma and Medilink bring momentum with positive results.
- 13 AI drug discovery companies you should know aboutLabiotech.eu ·
Take a look at 13 of the top AI drug discovery companies around today, using their technology to speed up the drug discovery process.
- The next big shake-up in the GLP-1 market? (Part 1 of 3)Labiotech.eu ·
In part one of our series, I’m joined by Valeriia Simanovskaia, founder and CEO of BioBrokers, an independent capital markets and strategic advisory firm for life sciences.
- The Metabolic Moment: 3 big bets to watch in metabolic diseaseLabiotech.eu ·
Explore three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy for diabetes.
- Preclinical Pulse: The research catching our eye in October 2026Labiotech.eu ·
Find out about six preclinical assets that caught our attention in the October edition of Labiotech's Preclinical Pulse.
- Pushing biotech forward in France: 10 companies to know aboutLabiotech.eu ·
France is at the forefront of innovative biotech and Paris has become a vibrant startup ecosystem. Here are 10 top French biotech companies.
- How to choose lab consumables: A guide to sterility, performance, and sustainabilityLabiotech.eu ·
Lab consumables can affect sterility, contamination, reproducibility, and yield. Learn what to consider when selecting high-quality consumables.
- Different clusters in different regions: what’s life sciences in Finland like?Labiotech.eu ·
Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science industry.
- More options, better odds: the changing prostate cancer treatment landscapeLabiotech.eu ·
As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space.
- Saudi Arabia’s biotech momentum: inside RGMBS 2026Labiotech.eu ·
Today, we are joined by Abdulaziz Aldayel, from the King Abdullah International Medical Research Center to discuss the Riyadh Global Medical Biotechnology Summit.
- From strong science to mature companies: The next test for Spanish biotechLabiotech.eu ·
Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges in later stages.
- Top biotech deals in September 2026Labiotech.eu ·
September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals.
- Viatris’s pipeline strategy: Moving beyond generics to find new growthLabiotech.eu ·
Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find new growth.
- Merck’s new BioReliance® Facility in Darmstadt: supporting biologics development and commercialization in EuropeLabiotech.eu ·
Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability studies in Europe.
- The biggest biotech funding rounds in September 2026Labiotech.eu ·
The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August 2026.
- BIOSPAIN 2026: The challenge of turning strong science into scaleLabiotech.eu ·
BIOSPAIN returned to Bilbao this week with much of the conversation focused not so much on whether Spain, and more broadly, Europe, can produce strong biotech science, but on what happens next.
- How Flagship’s Valo is reshaping AI drug discovery with human dataLabiotech.eu ·
AI has been one of the biggest buzzwords in biotech for years now but actual R&D productivity gains have been hard to find.
- How macrocyclic drugs are gaining momentum in the cardiometabolic disease spaceLabiotech.eu ·
Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.
- Changing with the times: what is the future of biomarkers in neurology?Labiotech.eu ·
Biomarkers that reflect the brain’s workings have been difficult to pin down in neurology studies, but the field has come a long way.
- Nine biotech companies you should know about in SpainLabiotech.eu ·
Take a look at some of the top biotech companies you can find in Spain, whose biotech industry has grown dramatically in the last decade.
- Key considerations for adopting automated liquid handling platforms in pharmaceutical workflowsLabiotech.eu ·
From selecting the right system to overcoming integration challenges, discover how automated liquid handling can support flexible, reproducible laboratory workflows.